Torsdag 26 December | 20:03:54 Europe / Stockholm

Kalender

Tid*
2025-03-06 N/A Kvartalsrapport 2025-Q2
2024-11-11 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2024-11-08 - Årsstämma
2024-09-20 - Bokslutskommuniké 2024
2024-03-07 - Kvartalsrapport 2024-Q2
2023-11-17 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2023-11-16 - Årsstämma
2023-09-28 - Bokslutskommuniké 2023
2023-04-24 - Extra Bolagsstämma 2023
2023-03-23 - Kvartalsrapport 2023-Q2
2022-11-17 - Årsstämma
2022-10-25 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 - Bokslutskommuniké 2022
2022-06-29 - Extra Bolagsstämma 2022
2022-02-24 - Kvartalsrapport 2022-Q2
2021-10-29 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 - Årsstämma
2021-09-15 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.
2021-10-28 17:15:00

Company release
28 October 2021 at 6:15 p.m. (EEST)

Nightingale Health Plc's Annual General Meeting, held on 28 October 2021, adopted the financial statements and discharged the members of the Board of Directors and the CEO from liability for the financial period of 1 July 2020-30 June 2021. The Annual General Meeting approved in an advisory decision the remuneration report and remuneration policy of governing bodies.

Use of the profit shown on the balance sheet and the payment of dividend

The General Meeting resolved in accordance with the proposal of the Board of Directors that, based on the balance sheet adopted for the financial period ended on 30 June 2021, no dividend will be distributed.

The Board of Directors and the Auditor

The number of members of the Board of Directors was confirmed to be seven members. Tom Jansson, Antti Kangas, Olli Karhi, Lotta Kopra, Leena Niemistö, Timo Soininen and Teemu Suna were re-elected as members of the Board of Directors.

The members of the Board of Directors are paid a monthly remuneration of EUR 2,000.

Authorised Public Accounting firm PricewaterhouseCoopers Oy was elected as the Auditor with Valtteri Helenius as the Responsible Auditor. The remuneration of the Auditor will be paid in accordance with a reasonable invoice approved by the company

Decisions by the Board of Directors of Nightingale Health Plc

The organisational meeting of the Board of Directors elected from among its members Timo Soininen as its Chair. The other members of the Board of Directors are Tom Jansson, Antti Kangas, Olli Karhi, Lotta Kopra, Leena Niemistö and Teemu Suna.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified advisor:
Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals' preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.